Abstract
Plexiform neurofibromas (PN) are congenital tumors that affect up to 50% of individuals with neurofibromatosis type 1. Despite their benign nature, they can grow rapidly and cause severe morbidities. Selumetinib, an inhibitor of mitogen-activated protein kinase (MEK) 1 and 2, was reported to induce a clinical response in pediatric subjects with inoperable PN. The aim of this paper is to describe a prospective case series of patients treated with selumetinib with emphasis on drug adverse events. All the subjects who received selumetinib at the Pediatric Department of Scientific Research Institute and Hospital "Burlo Garofolo", from November 2017 to January 2020, were progressively included. We monitored the patients with a follow-up visit every 3 months. MRI or CT scans to monitor the growth of the tumor were performed after 3 months of treatment, and then every 6-9 months. Selumetinib was prescribed to nine children, with a total of 17 inoperable PN. The mean follow-up period was 12 months. During the follow-up, one patient experienced an ischemic stroke, unrelated to the treatment. Only minor adverse events were observed: six individuals developed gastrointestinal side effects, seven patients presented a mild form of acne, six...Continue Reading
References
Jun 21, 2001·Neurology·M Ruggieri, S M Huson
Jan 19, 2005·Archives of Dermatology·Marga LammertVictor F Mautner
Mar 3, 2005·Journal of Neurosurgery·Daniel H KimDavid G Kline
Jan 12, 2007·Neurology·E DombiB C Widemann
Oct 6, 2012·Orphanet Journal of Rare Diseases·Rosa NguyenVictor-Felix Mautner
Oct 27, 2012·The Lancet Oncology·Kent A RobertsonD Wade Clapp
Aug 13, 2013·Handbook of Clinical Neurology·Rosalie E Ferner, David H Gutmann
Oct 30, 2013·Journal of Neuro-oncology·Rosa NguyenVictor-Felix Mautner
Oct 22, 2015·Archives of Disease in Childhood. Education and Practice Edition·B M Dunning-Davies, A P J Parker
Dec 29, 2016·The New England Journal of Medicine·Eva DombiBrigitte C Widemann
Feb 24, 2017·Nature Reviews. Disease Primers·David H GutmannKimberly J Johnson
Mar 8, 2017·BMC Cancer·Patricia M LoRussoRoger B Cohen
Aug 5, 2017·Pediatric Blood & Cancer·Amedeo A AziziTatjana Traub-Weidinger
Nov 15, 2017·Japanese Journal of Clinical Oncology·Takashi SetoKoichi Fukino
May 26, 2018·Acta Dermato-venereologica·Yuichi YoshidaOsamu Yamamoto
Sep 4, 2018·Ecancermedicalscience·Honoré PapaliaNicolas André
May 30, 2019·Neuropediatrics·Pia VaassenThorsten Rosenbaum
Jun 4, 2019·The Lancet Oncology·Jason FangusaroMaryam Fouladi
Dec 29, 2019·BMC Cancer·Sébastien PerreaultNada Jabado
Jan 10, 2020·Pediatric Neurology·João PassosSofia Nunes
Feb 29, 2020·Journal of Neuro-oncology·Vera Espírito SantoSofia Nunes
Mar 19, 2020·The New England Journal of Medicine·Andrea M GrossBrigitte C Widemann